
Equillium, Inc.
NEWS
There was a handful of positive clinical trial news reported today. Here’s a look.
It was a surprisingly big week for clinical trial updates related to COVID-19, although there was plenty of non-COVID-19 news as well. Here’s a look.
Itolizumab is a first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 13, 2020.
JOBS
IN THE PRESS